Concord BiotechQ2 FY25

Concord Biotech Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹554.8P/E: 39.1Market Cap: ₹11.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Concord Biotech expects double-digit growth in API sales for FY25, with mid- to high-teen growth projected going forward.
  • Formulation segment growing strongly with 125% growth in Q2 and 87% in H1 FY25; full year expected to maintain around 20-26% share with ongoing growth.
  • Long-term guidance maintains an 80-20 revenue mix between API and formulation segments.
  • Pipeline includes launching 2-3 new products annually over the next 3-5 years, targeting a combined market potential of ~$1 billion at API level.
  • Focus on niche, complex fermentation-based APIs with limited competition, particularly in immunosuppressants, oncology, antifungals, and anti-infectives.
  • Export markets expected to grow faster than domestic markets, expanding global market share.
  • Injectables commercialization expected by February 2025, initially targeting Indian market and then emerging markets, with a potentially faster ramp-up.
  • Overall revenue growth driven primarily by volume expansion rather than pricing increases.

See what Concord Biotech management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The company indicated that current capital expenditure is primarily maintenance capex.
  • They have significant cash reserves available.
  • If fewer opportunities arise for inorganic growth, they may explore organic growth strategies.
  • Regarding inorganic growth, their focus would be on adjacencies to fermentation.
  • There is no mention of any current or planned fundraising through debt or equity in the transcript.
  • The company maintains a zero-debt status with cash and cash equivalents of INR 284 crores as of September 30, 2024.

See what Concord Biotech management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Current capex is primarily maintenance-focused.
  • The company has significant cash reserves.
  • If fewer inorganic growth opportunities arise, organic growth strategies may be explored.
  • Inorganic growth criteria focus on adjacencies to fermentation.
  • No specific lumpiness or large new capital projects were highlighted.
  • Injectable facility commercialization is expected by February 2025, delayed due to media fill studies and regulatory approvals rather than capex constraints.
  • Capacity utilization across units indicates operational capacity for growth without immediate large capex.

Track Concord Biotech — get its next earnings analysis in your feed

How does Concord Biotech rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisConcord Biotech
Rev 3Mar 3

How does Concord Biotech rank in Pharmaceuticals & Biotechnology?

Compare Concord Biotech against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →